Introduction
interfered with progession of structural damage in experimental chronic renal failure [10] . The question It is generally accepted that hypertension and proarises whether, in analogy to the message from the teinuria are the two most important progression factors ELITE study, Ang II receptor blockers are superior to in chronic renal failure [1] . Antihypertensive drugs ACE inhibitors in renal failure as well. Some points slow progression, and this has been attributed mainly relating to these issues will be discussed here. to their blood-pressure-lowering effect. It is generally agreed, however, that in various types of chronic renal failure [2-4] angiotensin-converting enzyme (ACE) Sympathetic control of heart and kidney inhibitors are superior to other drugs. To explain such renoprotective properties of ACE inhibitors, multiple Both kidney and heart are densely innervated by the haemodynamic and growth mechanisms have been sympathetic nervous system. The renal sympathetic proposed relating either to diminished production of nerves control renal blood flow, renin secretion, and Ang II or accumulation of nitric oxide (NO) [5, 6 ] . sodium reabsorption [11] . The cardiac nerves regulate Today Ang II receptor antagonists are available as cardiac output by influencing heart rate and contractilan alternative to ACE inhibitors. They block the ity. Noradrenaline acts at the postganglionic neuroactions of Ang II by an interaction with the AT 1 effector junctions through adrenoceptors that are receptor. It has remained unresolved, however, whether divided in three classes: a 1 , a 2 and b receptors. In each Ang II receptor antagonists are equivalent or even class at least three subtypes have been cloned [12] . superior to ACE inhibitors in the treatment of hyper-
The amount of noradrenaline present at the receptor tension in chronic renal failure. In the 'Evaluation of sites is determined by the firing rate of the sympathetic losartan in the elderly' ( ELITE) study the mortality nerves, the rate of reuptake into the neurone, and the of patients with heart failure treated with an Ang II operation of presynaptic receptors. Presynaptic recepreceptor blocker was lower when compared to an ACE tors are structures within the membrane of sympathetic inhibitor [7] . The higher mortality of patients treated nerve endings (Figure 1 ), which when activated either with an ACE inhibitor was mainly due to sudden enhance or inhibit the amount of noradrenaline cardiac death. There is now also experimental evidence released per nerve impulse into the synaptic cleft. Of to suggest more complete suppression of cardiac norspecial importance are presynaptic receptors, which adrenaline release by Ang II receptor blockers than by are activated by endogenous ligands such as noradrena-ACE inhibitors [8] from Ang I or locally within various cardiovascular ) and bradykinin (B 2 ) receptors respectively. Losartan ( EXP 3174) prevents Ang II-mediated facilitation without interfering with bradykinin degradation by kininase (ACE ). Captopril is not able to prevent Ang II formation, since non-ACE pathways convert Ang I to Ang II. Captopril protects bradykinin from degradation by kininase and enables bradykinin to enhance NA release.
tissues such as blood vessels, heart, and kidney [21] . bradykinin to inactive fragments. There are two types of bradykinin receptors, i.e. B 1 and B 2 receptors. Most Ang II dose dependently enhances noradrenaline release in isolated rat and human renal cortical [22, 23] of the biological actions of bradykinin are mediated by the B 2 subtype. Bradykinin has a positive inotropic and right atrial slices [24] by up to 80%. This effect is due to activation of Ang II receptors of the AT 1 effect in rat atria [27] secondary to B 2 -receptormediated facilitation of noradrenaline release [24, 28] . subtype, since it is blocked by EXP 3174, the active metabolite of the selective Ang II receptor antagonist In the rat, this faciliatatory effect is observed in the absence of kininase I blockade, but can be potentiated losartan (Figure 1) . AT 2 receptor antagonists have no effect in human renal cortex [23] . For the modulation by ACE inhibitors [24, 27] . In contrast, in human atria and renal cortex [23, 24] , the enhancing effect of bradyof noradrenaline release by Ang II within cardiovascular tissue, locally formed Ang II is probably more kinin on noradrenaline release is seen only when its degradation by kininase is prevented by an ACE important than the peptide formed in the circulation. Ang I, the precursor of Ang II, increases noradrenaline inhibitor (Figure 1 ). The ACE activity is apparently higher in human compared to rat atrium, so that the release in human renal cortex and atrium almost as effectively as does Ang II. This facilitatory effect of facilitatory effect of bradykinin is clinically relevant only in the presence of ACE inhibition ( [23] . Thus, system interact. Sympathetic overactivity leads to even in the presence of ACE inhibitors, Ang II may increased formation and release of renin through be formed locally from Ang I by non-ACE pathways activation of b-adrenoceptors [29] by noradrenaline. [8, 21] in the heart and kidney to enhance noradrenaline On the other hand, Ang II thus formed will act back release ( Figure 1) .
to activate presynaptic Ang II (AT 1 ) receptors and further enhance noradrenaline release. This sequence of events has been proposed in severe congestive heart Effects of bradykinin on catecholamine release in failure [30] . This circulus vitiosus contributes to the the atrium of the heart and the kidney high plasma noradrenaline concentrations in heart failure, which predict poor survival: noradrenaline is proarrhythmic, leads to b-adrenoceptor downregulBradykinin is a peptide that is formed locally by the enzyme kallikrein from the substrate kininogen and by ation, and has growth-promoting effects via a and b adrenoceptors [31] . aminopeptidases from the peptide kallidin [25, 26 ] . Kininase I, which is identical with ACE, degrades Our findings that the ACE inhibitor captopril unmasks a noradrenaline-enhancing effect of brady-and appear sound enough to be communicated at this early stage to the nephrological community. kinin and does not fully block the effects of Ang I may have some clinical implications. In the ELITE study plasma levels of noradrenaline decreased in the losartan References There is no such thing as 'renal arrythmia'. There is no doubt that introduction of ACE inhibitor 15. Rump LC, Schwertfeger E, Schuster MJ, Schaible U, therapy has been a milestone in the treatment of heart Frankenschmidt A, Schollmeyer P. Dopamine DA 2 -receptor activation inhibits noradrenaline release in human kidney slices. Nevertheless, these arguments are of sufficient interest
